<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638131</url>
  </required_header>
  <id_info>
    <org_study_id>BOS-ND-2007</org_study_id>
    <nct_id>NCT00638131</nct_id>
  </id_info>
  <brief_title>Bosentan Use in Patients With Diabetic Nephropathy</brief_title>
  <official_title>Effect of Bosentan on Systemic and Renal Inflammatory Markers in Patients With Diabetic Nephropathy on Angiotensin II Receptor Blockers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is little doubt of the necessity for further improvement in the prevention and therapy&#xD;
      of end-stage renal disease. Despite the success of ARB in treating diabetic nephropathy, not&#xD;
      all patients obtain satisfactory control of blood pressure, albuminuria and decline in renal&#xD;
      function. Experimental data have provided us with a rationale for the potential added&#xD;
      benefits of ET receptor blockade to the AII inhibition in diabetic renal protection.&#xD;
      Considering the nephroprotective effect of bosentan in diabetic rats, clinical studies are&#xD;
      warranted to assess whether ET receptor antagonism has additive renoprotective effects on top&#xD;
      of AII inhibition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    problem of recruitment&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline to week 16 in renal functioning. The following renal function parameter will be measured: - 24h UAE;</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo given bid same as experimental arm;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women ≥ 18 years of age with a body weight of ≥ 40 kg;&#xD;
&#xD;
          -  For female patients, only non-pregnant women who are surgically sterile,&#xD;
             postmenopausal or have documented infertility (over 50 years of age and amenorrheic&#xD;
             for at least 1 year), or those of childbearing potential using intrauterine devices&#xD;
             (IUDs);&#xD;
&#xD;
          -  Patients diagnosed Type 2 diabetes with overt nephropathy (urinary albumin excretion ≥&#xD;
             300mg/24h);&#xD;
&#xD;
          -  Patients on current treatment with angiotensin II receptor blockers for ≥ 3 months;&#xD;
&#xD;
          -  Patients stable for at least 3 months prior to screening (no change in medications for&#xD;
             diabetic nephropathy);&#xD;
&#xD;
          -  Provide written informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of pulmonary chronic obstructive disease, cardiac failure or&#xD;
             coronary artery disease;&#xD;
&#xD;
          -  Patients with documented cancers, acute infections or chronic inflammatory diseases;&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding;&#xD;
&#xD;
          -  Patients with known hepatic disorders or AST and ∕or ALT upper than normal limit;&#xD;
&#xD;
          -  Patients with hemoglobin or hematocrit that is ≥ 30% below the normal range (patients&#xD;
             with secondary polycythemia are permitted);&#xD;
&#xD;
          -  Patients with systolic blood pressure &lt; 110mm Hg;&#xD;
&#xD;
          -  Patients with plasmatic albumin level &lt; 30g/L;&#xD;
&#xD;
          -  Patients with a documented creatinine clearance ≤ 60ml/min;&#xD;
&#xD;
          -  Patients on anticoagulants or anti-inflammatory drugs, including cyclooxygenase&#xD;
             inhibitors, AINS, prednisone and immunosuppressive drugs, platelet aggregation&#xD;
             inhibitors, except low dose aspirin, ACE inhibitors, antidiabetic agents&#xD;
             (rosiglitazone, pioglitazone) and antioxidants (vitamin E)(except statins or low-dose&#xD;
             aspirin ≤ 80mg/day);&#xD;
&#xD;
          -  Patients on treatment or planned treatment with another investigational drug;&#xD;
&#xD;
          -  Patients who are receiving an endothelin receptor antagonist, phosphodiesterase type 5&#xD;
             inhibitor, or with a prostanoid (excluding acute administration during a&#xD;
             catheterization procedure to test vascular reactivity) within 2 months of inclusion;&#xD;
&#xD;
          -  Patients who are receiving calcineurin-inhibitors (i.e., cyclosporine A and&#xD;
             tacrolimus), fluconazole, glibenclamide (glyburide) at inclusion or are expected to&#xD;
             receive any of these drugs during the study;&#xD;
&#xD;
          -  Patients with a known hypersensitivity to bosentan or any of the excipients;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryse Courteau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

